Safety and Efficacy of γδ T Cell Against Gastric Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02585908|
Recruitment Status : Not yet recruiting
First Posted : October 26, 2015
Last Update Posted : November 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Gastric Cancer||Biological: CIK Biological: γδ T Biological: CIK and γδ T||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||γδ T Cell Immunotherapy for Treatment of Gastric Cancer|
|Estimated Study Start Date :||December 2019|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2022|
No Intervention: Experimental Group A(control group)
regular treatment and follow up
Experimental: Experimental Group B
CIK will be used against tumor cells.
CIK cells will be used against tumor cells.
Experimental: Experimental Group C
γδ T will be used against tumor cells.
Biological: γδ T
γδ T cells will be used against tumor cells.
Experimental: Experimental Group D
CIK and γδ T will be used against tumor cells.
Biological: CIK and γδ T
CIK and γδ T cells will be used against tumor cells.
- Reduced size of the tumor. [ Time Frame: up to one year ]Tumor load will be evaluated by RECIST criteria.
- Safety, as measured by the rate of adverse events and serious adverse events [ Time Frame: up to two years ]Safety, as measured by the rate of adverse events and serious adverse events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02585908
|Contact: xie yanyun, email@example.com|
|Contact: li gangyi, firstname.lastname@example.org|
|The First Affiliated Hospital of Guangzhou Medical University|
|Guangzhou, Guangdong, China, 510120|
|First Affiliated Hospital of Henan University of Science and Technology|
|Luoyang, Henan, China, 471003|
|Huai'An First People'S Hospital|
|Huaian, Jiangsu, China, 223300|
|Hangzhou Cancer Hospital|
|Hangzhou, Zhejiang, China, 310002|
|Study Chair:||li gangyi, master||Beijing Doing Biomedical Co., Ltd.|